NASDAQ · STOCK
Dexcom
$74.97
52W $54.11 – $89.98
72/100
$27.93B
29.3
1.43
Price History (6M)
Executive Summary
5 analysts weighed in with 100% agreement on a bullish lean. Growth Analyst: Quarter-over-quarter growth rate is ACCELERATING, not just positive. Overall recommendation: BUY.
Bull & Bear Case
Bull Case
- Positive MACD histogram signals bullish momentum.
- Daily trend: uptrend.
- Daily uptrend conflicts with weekly downtrend — buying against the higher timeframe trend is higher risk.
- Daily volatility (ATR%) above ~3% is treated as elevated risk.
Bear Case
- Stochastic RSI (92.8) confirms overbought conditions.
- Weekly trend is bearish while daily is bullish — against the higher-timeframe trend.
AI Investment Committee
Committee Consensus
As of July 11, 2026
Overall Committee Score
72/100
Agreement
100%
Analysts
5
Conviction
Unanimous
Growth Analyst
bullish
85
/ 100 · Low confidence
Strong, accelerating growth with consistent execution
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
Macro Analyst
bullish
70
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst
bullish
68
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.33 across 17 articles, 14d)
Portfolio Manager
bullish
75
/ 100 · Low confidence
The existing book is healthy enough that position-sizing here is a matter of stock selection, not portfolio constraints
+ Portfolio position concentration is currently healthy
Technical Analysis
RSI (14)
66.1
Neutral
MACD Histogram
0.283
Bullish Momentum
Trend Direction
Uptrend
Weekly: Sideways
Market Structure
Mixed
Support
$74.90
Resistance
$75.93
Bollinger %B
0.83
Inside Bands
Price vs Moving Averages
EMA 9
$72.56
Above
EMA 21
$71.72
Above
EMA 50
$70.00
Above
EMA 200
$69.71
Above
Fundamental Analysis
Valuation
21
Growth
76
Profitability
99
Financial Health
95
Valuation
P/E Ratio
29.3×
P/B Ratio
9.43×
PEG Ratio
—
Dividend Yield
—
52W High
$89.98
52W Low
$54.11
Quality & Growth
ROE
3383.0%
ROA
1339.0%
Gross Margin
6343.0%
Operating Margin
2145.0%
Revenue Growth YoY
+1615.0%
Debt / Equity
0.47
AI Fundamental Assessment
P/E ratio of 29.3 (moderate relative to a 15-40x range); Price-to-book of 9.4x; Revenue growth (YoY) of 16.1%; EPS growth (YoY) of 77.5%; Return on equity of 33.8%; Return on assets of 13.4%; Net margin of 19.3%; Gross margin of 63.4%; Current ratio of 1.88 (healthy short-term liquidity); Debt-to-equity of 0.47; Most recent quarter beat estimates by 17.0%; EPS growth accelerating (-26.2% -> +24.4% QoQ); Analyst estimates falling over recent quarters
Key Risks
- Stochastic RSI (92.8) confirms overbought conditions.
- Weekly trend is bearish while daily is bullish — against the higher-timeframe trend.
This risk summary is generated from quantitative data signals, not qualitative opinion. All investors should conduct their own due diligence. This is not financial advice.
Get the Full DXCM Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Mobile